An optimized HPLC-MS/MS assay for uracil and dihydrouracil in plasma: Improving dihydropyrimidine dehydrogenase phenotyping for individualized fluoropyrimidine treatment.

Abstract excerpt

Dihydropyrimidine dehydrogenase (DPD) is a key phase I drug-metabolizing enzyme responsible for catabolizing fluoropyrimidine chemotherapeutics such as 5-fluorouracil, capecitabine and tegafur. Its activity shows marked interindividual variability due to both genetic polymorphisms and environmental factors. Reduced DPD activity results in excessive fluoropyrimidine exposure, potentially causing severe and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chromatography, High Pressure Liquid
• Share to Dihydrouracil Dehydrogenase (NADP)